Introduction
DLBCL
SOLID TUMORS
Bromodomain and extraterminal proteins (BET) are epigenetic readers that bind to acetylated lysine residues on histones in chromatinTrotabresib (CC-90010; BMS-986378) is an orally administered, potent, reversible inhibitor of BET family members. CC-90010-ST-001 is a phase I, multicenter, open-label study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of trotabresib in patients with advanced or unresectable solid tumors or relapsed/refractory (R/R) DLBCL. The dose escalation (part A) of this trial evaluated a wide range of doses and treatment schedules, with the intention of optimizing the treatment-free interval in each treatment cycle to improve the tolerability of the dose selected for further evaluation in the expansion cohortsHere, we report long-term follow-up of safety and efficacy from the dose escalation (part A) and, for the first time, present results from the dose-expansion cohorts (parts B and C), including evaluation of food effects on trotabresib safety and PK.